UOC
ALPN

UBS O'Connor’s Alpine Immune Sciences Inc ALPN Stock Holding History

UBS O'Connor’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-25,000
Closed -$1.52M – 798
2015
Q2 		$1.52M Buy
+25,000
New +$1.49M 0.01% 485

Other funds holding ALPN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS O'Connor's ALPN Position: Q3 2015 in Review

UBS O'Connor sold out of Alpine Immune Sciences Inc (ALPN) in Q3 2015, closing a stake of 25,000 shares — an estimated $1.52M sold.

UBS O'Connor first reported a position in ALPN in Q2 2015 and held it in 1 quarter. The position peaked at $1.52M in Q2 2015. 63 funds tracked by Wall St. Rank hold ALPN as of Q3 2015.

  • UBS O'Connor reported no remaining Alpine Immune Sciences Inc position as of Q3 2015 after selling out during the quarter.
  • UBS O'Connor sold 25,000 Alpine Immune Sciences Inc shares in Q3 2015, an estimated $1.52M.
  • UBS O'Connor first reported a position in Alpine Immune Sciences Inc in Q2 2015 and held it in 1 quarter.
  • UBS O'Connor's Alpine Immune Sciences Inc position peaked at $1.52M in Q2 2015.
  • 63 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q3 2015.

Based on UBS O'Connor's 13F filing for Q3 2015, filed 13 Nov 2015.